bevacizumab indicated for the treatment of KRAS-mutated metastatic colorectal cancer. Data from the study showed that 12 of 35 (34%) patients treated with the recommended Phase 2 dose (RP2D) attained a complete response (1 patient) or partial response (11 patients). The toxicity profile of the combination also appeared relatively tame with no major or unexpected toxicities ascribed to onvansertib.
https://www.tipranks.com/news/article/dont-say-bye-bye-to-cardiff-stock-say-buy-buy-analyst?utm_source=advfn.com&utm_medium=referral